The Service of the Commission for the Protection of Competition has received a notification of a concentration concerning the proposed acquisition of assets related to the portfolios of medicinal products for the central nervous system and pain/cardiology sector which belong to Sanofi S.A., by Permira Holdings Ltd, via Laboratorios Lesvi S.L.U..
Permira Holdings Ltd is a company duly registered in accordance with the laws of Guernsey. Permira is a global private equity company that proceeds to long-term investments in companies operating in a wide range of sectors with growth and development potential. It is the parent company of neuraxpharm Arzneimittel GmbH and Laboratorios Lesvi S.L.U..
Neuraxpharm Arzneimittel GmbH is a company duly registered in accordance with the laws of Germany. Neuraxpharm is a specialized pharmaceutical company which focuses in the manufacturing and sale of pharmaceuticals for the treatment of disorders of the central nervous system.
Laboratorios Lesvi S.L.U. is a company duly registered in accordance with the laws of Spain. It is a business-to-business (B2B) provider with full production service for pharmaceutical forms of final dosage. It is mainly active in the field of the central nervous system. However, its portfolio also consists of antiemetic, anti-infective, cardiovascular, painkillers and respiratory products.
Targets in this practice are specific assets comprising two portfolios of pharmaceutical products, one for the central nervous system and one for the pain/cardiology sector, currently owned by Sanofi S.A. and some of Sanofi's affiliates.